Triple-negative breast cancer (TNBC), which accounts for 10–20% of all breast cancers, does not express estrogen receptors (ERs) or progesterone receptors (PRs) and lacks human epidermal growth factor receptor-2 (HER2) amplification. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.